Showing results (1361-1370 of 1,518) with videos related to
Sort By:
Pageof 152
European Journal of Cancer (Oxford, England : 1990)|June 14, 2019
Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trialMartin Reck, Michael Schenker, Ki Hyeong Lee, et al.Nature Medicine|March 17, 2023
A longitudinal circulating tumor DNA-based model associated with survival in metastatic non-small-cell lung cancerZoe June F Assaf, Wei Zou, Alexander D Fine, et al.Nature Communications|October 15, 2025
Low circulating miR-190a-5p predicts progression of chronic kidney diseaseDavid P Baird, Jinnan Zang, Katie L Connor, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 12, 2014
Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancerJoachim von Pawel, Robert Jotte, David R Spigel, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 17, 2018
Randomized phase III study of docetaxel plus bavituximab in previously treated advanced non-squamous non-small-cell lung cancerD E Gerber, L Horn, M Boyer, et al.The Lancet. Oncology|February 10, 2020
Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trialMarina C Garassino, Shirish Gadgeel, Emilio Esteban, et al.Journal of the American Academy of Dermatology|December 7, 2021
Medical adhesive allergens: Retrospective analysis of cross-sectional data from the North American Contact Dermatitis Group, 2001-2018Amber Reck Atwater, Raina Bembry, Beiyu Liu, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 12, 2022
Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 TrialMarina C Garassino, Julien Mazieres, Martin Reck, et al.Lung Cancer (Amsterdam, Netherlands)|December 2, 2017
Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancerMartin Reck, Luis Paz-Ares, Paolo Bidoli, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 28, 2017
Current and Emergent Therapy Options for Advanced Squamous Cell Lung CancerMark A Socinski, Coleman Obasaju, David Gandara, et al.Pageof 152